DIPG-21. GENOMIC LANDSCAPE OF THE FIRST 100 TUMORS REGISTERED IN THE BIOLOGICAL MEDICINE FOR DIPG ERADICATION (BIOMEDE) TRIAL

BACKGROUND: Genomic analyses of DIPG have been so far mostly performed on autopsy samples or in retrospective studies. In the frame of the BIOMEDE randomized trial of three targeted therapies (erlotinib, everolimus, dasatinib) based on three biomarkers (EGFR, PTEN and PDGFRA respectively), a systema...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Castel, David, Barret, Emilie, Picot, Stephanie, Plessier, Alexandre, Le Dret, Ludivine, Nysom, Karsten, Huybrechts, Sophie, Capolino, Perrine, Le Deley, Marie-Cecile, Vassal, Gilles, Puget, Stephanie, Varlet, Pascale, Grill, Jacques, Debily, Marie-Anne
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2017
Teme:
Abstracts
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5475015/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox083.036
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items